Matthew Aboudara, MD
Pulmonary Disease · Kansas City, MONPI 1659475135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,280 of the $29,614 with a category attached, or 61.7%. Medtronic accounts for 70.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $10,123 and has fallen 74.0% since, to $2,632 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $271.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Pulmonx Corporation$3K
- Covidien LP$2K
- Intuitive Surgical$1K
- Noah Medical Corporation$1K
- Boston Scientific$867
- plus $283 from 3 others
What the payments were for
- Consulting fees$2,4338%
- Speaking & faculty fees$18,28062%
- Travel & lodging$5,50119%
- Food & beverage$3,40011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 47 | $20,888 |
| Pulmonx Corporation | 12 | $3,128 |
| Covidien LP | 13 | $1,943 |
| Intuitive Surgical | 9 | $1,426 |
| Noah Medical Corporation | 15 | $1,078 |
| Boston Scientific | 9 | $867 |
| Broncus Medical | 1 | $177 |
| Pinnacle Biologics, Inc | 2 | $61 |
| Olympus America Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$12,230
- superDimension$5,504
- Pulmonx Endobronchial Valve EBV$2,850
- Da Vinci Surgical System$1,151
- ACQUIRE$750
- GALAXY$700
- CHARTIS CATHETER$129
- ZEPHYR DELIVERY CATHETER$129
- ZEPHYR ENDOBRONCHIAL VALVE$129
- PULMONX CHARTIS TABLET CONSOLE$129
How this compares
$29,614 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,778 |
| Tiotropium Bromide | 11 | $4,261 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,122 |
| Arnuity ElliptaFluticasone Furoate | 15 | $2,830 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $703 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Kansas City
- Timothy SmithKansas City$104K
- Andrea CoveyKansas City$23K
- Timothy SaetteleKansas City$13K
- James LadesichKansas City$12K
- Andrew BozarthKansas City$11K
- Azzam ParoyaKansas City$10K
- Hamza AlshamiKansas City$10K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.